sign in sign up
<<
Home , Carnidazole, Cefuroxime axetil

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY VOLUME 28 * DECEMBER 1985 * NUMBER 6 Robert C. Moellering, Jr., Editor in Chief (1990) George A. Jacoby, Jr., Editor (1990) New England Deaconess Hospital Massachusetts General Hospital Boston, Mass. Boston Michael Barza, Editor (1990) Christine C. Sanders, Editor (1989) New England Medical Center Hospitals Creighton University School of Medicine Boston, Mass. Omaha, Neb. Herbert L. Ennis, Editor (1987) John A. Washington II, Editor (1986) Roche Institute of Molecular Biology Mayo Clinic Nutley, N.J. Rochester, Minn. I . Jack M. Gwaltney, Jr., Editor (1990) Peter G. Welling, Editor (1988) University of Virginia School of Medicine Warner-Lambert Co. Charlottesville Ann Arbor, Mich. EDITORIAL BOARD Norris Allen (1986) Arthur English (1986) R. Luthy (1986) W. Eugene Sanders, Jr. (1987) Vincent T. Andriole (1987) Robert J. Fass (1985) Francis L. Macrina (1985) W. Michael Scheld (1986) Bascom F. Anthony (1985) Stuart Feldman (1985) Gerald L. Mandell (1986) Jerome J. Schentag (1985) George R. Aronoff (1986) Sydney Finegold (1985) Gary R. Matzke (1986) Raymond F. Schinazi (1986) Robert Austrian (1986) Robert J. Fitzgerald (1986) George H. McCracken (1987) Fritz D. Schoenknecht (1986) Richard H. Baltz (1987) Martin Forbes (1986) Antone A. Medeiros (1987) F. C. Sciavolino (1985) Rashmi H. Barbhaiya (1986) John N. Galgiani (1987) Gerald Medoff (1986) William M. Shannon (1986) Arthur L. Barry (1986) Dale N. Gerding (1985) Michael Miller (1987) Charles Shipman, Jr. (1985) John G. Bartlett (1987) Anthony J. Glazko (1987) Barbara Minshew (1985) Robert W. Sidwell (1987) William M. Bennett (1987) Irving H. Goldberg (1985) Thomas P. Moyer (1986) P. Frederick Sparling (1987) Richard F. Bergstrom (1985) Scott M. Hammer (1986) Barbara E. Murray (1987) Harold Standiford (1985) Karen K. Biron (1987) W. Lee Hand (1986) John D. Nelson (1986) David A. Stevens (1986) Gerald P. Bodey (1986) H. Hunter Handsfield (1986) Harold C. Neu (1986) Stephen E. Straus (1987) Arthur E. Brown (1987) Joseph Hawkins, Jr. (1985) Lawrence A. Pachla (1987) R. Sutherland (1985) Lawrence E. Bryan (1985) Frederick G. Hayden (1987) Joseph S. Pagano (1987) Morton N. Swartz (1985) Ward Bullock (1987) Michael Higgins (1986) James T. Park (1985) Richard B. Sykes (1985) Tsun Chang (1986) David C. Hooper (1987) James E. Pennington (1986) Francis P. Tally (1987) Anthony Chow (1985) Richard Hornick (1986) T. J. Perun (1986) Alexander Tomasz (1985) C. Glenn Cobbs (1986) George Gee Jackson (1986) Lance R. Peterson (1985) Ralph Tompsett (1985) Paul S. Cohen (1986) James H. Jorgensen (1987) Michael Rein (1986) Francis L. S. Tse (1986) William A. Craig (1987) William J. Jusko (1986) W. H. G. Richards (1986) Richard J. Wallace, Jr. (1987) Naomi Datta (1987) A. W. Karchmer (1985) Richard Roberts (1985) Michael Waring (1987) Lawrence E. Day (1986) Donald Kaye (1985) Ian M. Rollo (1985) Bernard Weisblum (1985) William E. Dismukes (1987) George S. Kobayashi (1985) Allan Ronald (1987) Richard M. Welch (1986) R. Gordon Douglas, Jr. (1986) Donald J. Krogstad (1986) Richard Root (1986) Richard Wise (1986) John C. Drach (1987) Felix Leitner (1986) John P. Rosazza (1986) John S. Wolfson (1987) George L. Drusano (1987) Stephen A. Lerner (1986) Jon E. Rosenblatt (1985) Lowell Young (1985) Theodore Eickhoff (1985) Stuart B. Levy (1986) Robert H. Rubin (1987) Pauline K. W. Yu (1985) Gertrude B. Elion (1987) Joan Lusk (1986) Merle Sande (1985) Helen R. Whiteley, Chairman, Publications Board Linda M. Illig, Managing Editor, Journals John P. Evans, Production Editor Antimicrobial Agents and Chemotherapy (ISSN 0066-4804), an interdisciplinary publication of the American Society for Microbiology, 1913 I St., NW, Washington, DC 20006, is devoted to the dissemination of knowledge relating to all aspects of antimicrobial, , and anticancer agents and chemotherapy. Instructions to authors are published in the January issue each year; reprints are available from the editors and the Publications Department. Antimicrobial Agents and Chemotherapy is published monthly, and the twelve numbers are divided into two volumes per year. The nonmember subscription price is $157 per year; single copies are $21. The member subscription price is $31 (foreign, $41 [surface rate]) per year; single copies are $7. Correspondence relating to subscriptions, reprints, defective copies, availability of back issues, lost or late proofs, disposition of submitted manuscripts, and general editorial matters should be directed to the ASM Publications Department, 1913 I St., NW, Washington, DC 20006 (phone: 202 833-9680). Claims for missing issues from residents of the United States, Canada, and Mexico must be submitted within 3 months after publication of the issues; residents of all other countries must submit claims within 6 months of publication of the issues. Claims for issues missing because of failure to report an address change or for issues "missing from files" will not be allowed. Second-class postage paid at Washington, DC 20006, and at additional mailing offices. POSTMASTER: Send address changes to Antimicrobial Agents and Chemotherapy, ASM, 1913 I St., NW, Washington, DC 20006. Made in the United States of America. Copyright C 1985, American Society for Microbiology. B $ 1 tUtrA%f ( I'l3t° All Rights Reserved. The code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal use or for personal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per-copy fee through the Copyright Clearance Center, Inc., 21 Congress St., Salem, MA 01970, for copying beyond that permitted by Sections 107 and 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Author Index

Andrews, Richard J., 815 Dulworth, Jacqueline K., 745 Kluza, Ronald B., 791 Sedlock, David M., 786 Durack, David T., 751 Selman, Warren R., 839 Bailey, Denis M., 786 Leitner, F., 761 Silcox, Vella A., 807 Bartlett, Karen H., 842 Fass, Robert J., 834 Levi, Michael A., 730 Skog, Sven, 802 Bayer, Arnold S., 781 Frola, Frank N., 730 Linke, Michael J., 796 Soriano, Francisco, 845 Benjamin, Irving S., 778 Lismont, M. J., 756 Stanforth, David, 796 Berman, Jonathan D., 723 Gallalee, James V., 723 Luzzi, Ida, 847 Stenberg, Kjell, 802 Bien, Paul A., 766 Gerding, D. N., 849 Swenson, Jana M., 807 Blenkharn, J. Ian, 778 Ghazzouli, Ismail, 740 Mannisto, P. T., 812 Blumer, Jeffrey L., 839 Gianfrilli, Paola, 847 Marriott, Michael S., 815 Takai, Akira, 773 Blumgart, Leslie H., 778 Gibson, Robert N., 778 Matsen, John M., 829 Thompson, Bruce, 735 Bosso, John A., 829 Glupczynski, Y., 756 McDevitt, David A., 730 Thornsberry, Clyde, 807 Bothof, Theo, 824 Gotz, Vincent P., 727 McLaren, Colin, 740 Torney, Harry L., 745 Brammer, Keith W., 815 Griffin, Timothy J., 766 McNulty, Cliodna A. M., 837 Townsend, Paula L., 829 Brown, Allen L., 791 McPherson, Gilbert A. D., Trang, John M., 791 Buck, R. E., 761 Haanen, Clemens, 824 778 Tribukait, Bernhard, 802 Burns, William H., 740 Haataja, H., 812 Minami, Shinzaburou, 773 Troke, Peter F., 815 Habib, Nagy, 778 Misiek, M., 761 Tsai, Y. H., 761 Cafferkey, Mary T., 819 Heifetz, Carl L., 766 Mitsuhashi, Susumu, 773 Calia, Frank M., 735 Helsel, Valerie L., 834 Mok, Daniel, 778 Underwood, Fred L., 791 Cardines, Rita, 847 Herbst, John J., 829 Moody, J. A., 849 Chen, Ming S., 740 Holdrinet, Rob, 824 Van der Linden, M. P., 756 Cheng, Nick, 842 Hone, Rosemary, 819 Nearman, Howard S., 839 Viitanen, J., 812 Chisholm, D. R., 761 Norman, Dean, 781 Chow, Anthony W., 842 Inoue, Matsuhisa, 773 Wagner, Robin L., 832 Cohen, Michael A., 766 Pantosti, Annalisa, 847 Wallace, Richard J., Jr., 807 Cowan, Ronald I., 839 Jacobs, Richard F., 791 Pasculle, A. William, 730 Walzer, Peter D., 796 Creger, Richard J., 839 John, Lindsay, 778 Perfect, John R., 751 Thomas G., 791 Crokaert, F., 756 Johnson, David E., 735 Peterson, L. R., 849 Wells, Cushion, Melanie T., 796 Johnson, Jonas T., 832 Ponte, Carmen, 845 Wilhelmi, Isabel, 845 Jones, Steven, 832 Price, K. E., 761 Williams, Keith, 824 Danziger, Larry H., 839 Pursiano, T. A., 761 Wise, R., 837 de Neeff, Janine, 824 Kakizawa, Hiromi, 773 Dent, J., 837 Keane, Conor T., 819 Richardson, Kenneth, 815 Yasuda, Takashi, 773 de Pauw, Ben, 824 Kearns, Gregory L., 791 Yost, Richard L., 727 de Witte, Theo, 824 Kenny, Michael T., 745 Saikawa, Isamu, 773 Yotsuji, Akira, 773 Domagala, John M., 766 Kim, Ha-Kyung Cho, 832 Santamaria, Margarita, 845 Yourassowsky, E., 756 Dowling, John N., 730 Kim, Kwang Sik, 781 Saral, Rein, 740 Yu, Victor L., 832 ACKNOWLEDGMENT The following persons have served as invited special reviewers for the journal during 1985, and their help is greatly appreciated.

Robert Aber D. C. Eustice Walter Hughes Richard Platt Paul M. Sullam P. Actor Richard Facklam Lawrence Hurley David W. Ploth John Suttie John P. Anhalt D. Feingold Nilda Jacobus David Preston Thomas Sweeney Roger E. Bawdon James Ferry Mary Jo Jaqua Alice Prince Francis Szoka Arnold S. Bayer Coy D. Fitch Joseph John Stephen W. Queener Fred C. Tefiover G. Lopez-Berestein R. H. Fitzgerald, Jr. Ronald Jordan Edward Randinitis Clyde Thornsberry Jonathan D. lermhan Peter T. Frame G. Kaczorowski Jack S. Remington Robert Toothaker Michel Bergeron K. P. Fu Joan E. Kapusnik Donald Reynolds Lois Travis Howard Bockbrader Bruce Furie Arlyn Kinkel Janet A. Robertson Joseph G. Tully R. Wallace Brockman N. H. Georgapapadakou Vernon Knight Gary A. Roselle F. Valeriote J. Brunton W. Lance George Floyd C. Knoop R. W. Ryder K. Vosbeck Mildred K. Buening David Gilbert Wayne Koff Dennis Schaberg James Wade Edward A. Chaperon Frances Gillin Jordan Konisky Julius Schachter Richard J. Wallace, Jr. J. Chen Melvin R. Glick D. Lopatin Leonard W. Scheibel Hannah Wexler Charles E. Cherubin B. R. Goldin Joseph Marr Stephen C. Schimpff Lloyd Whitfield Richard B. Clark P. Goldman Robert E. McCabe Brian Scully Lee J. Wilkoff B. Louise Crandall Donald Goldmann Joel McDade Arzu Selen Temple Williams George Cuchural, Jr. Thotnas D. Gootz John E. McGown, Jr. Carol J. Shanholtzer Lynn Willis Robert E. Davis S. L. Gorbach Surendra Mehta William Shaw Walter R. Wilson Arnold L. Demain D. P. Griswold, Jr. John A. Montgomery John Sheagren Washington Winn R. E. DegJardins Jeffrey B. Hansen Roy Mundy John C. Sherris Charles Wisseman Louis S. Diamond William L. Hanson Carl W. Norden David Shlaes D. Scott Wright Thomas J. Dougherty Robert C. Hastings T. W. North G. D. Shockman David Wyler George Drusano J. Ho Stephen Olson Arnold L. Smith J. M. Wyss Herbert DuPont C. E. Hoffmann Gary D. Overturf Thomas F. Smith Milton J. Zmijewski Paul H. Edelstien Ian A. Holder Larry K. Pickering Herbert M. Sommers Michael Eldon Edward W. Hook III Dennis J. Pillion T. Spector George M. Eliopoulos Hua-Pin Huang Philip A. Pizzo V. Stollar U.S. Postal Service STATEMENT OF OWNERSHIP MANAGEMENT AND CIRCULATION Require; by 39 U.S.C 3685) IA TITLE OF PUBLICATION lB. PUBLICATION NO. 2. DATE OF FILING

Antimicrobial Agentq and Chemotherapy 1 October 1985 3. FREQUENCY OF ISSUE 3A. NO. OF ISSUES PUBLISHED 38. ANNUAL SUBSCRIPTION ANNUALLY PRICE Monthly 12 $31 mbr., $157 non- 4. COMPLETE MAILING ADDRESS OF KNOWN OFFICE OF PUBLICATION (Street, City, County. State and ZIP+d Code) (Not printers) mbr. American Society for Microbiology 1913 I Street, N.W., Washington, D.C. 20006 COMPLETE MAILING ADDRESS OF THE HEADQUARTERS OF GENERALBUSINESS OFFICES OF THE PUBLISHER (Not printer) (same as above) 6. FULL NAMES AND COMPLETE MAILING ADDRESS OF PUBLISHER EDITOR, AND MANAGING EDITOR (This item MUST NOT be blank) PUBLISHER (NJame and Complete MailinS Address) (same as above) EDITOR (Name and Complete Mailing Address) Robert C. Moellering, Jr. (same as above) JAGING EDITOR (Name and Complete Mailing Address) Linda M. Illig, acting (same as above) OWNER (If owned by a corporation its name and address must be stated and also Immediately thereunder the names and addresses ofstockholders owning or holding 1 percent or more of total amount ofstock. If not owned by a corporatIon the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated flrm, Its name and address, as well as that of each individual must be given. If the publica- lion is published by a nonprofit organization, Its name and address must be stated.) (Item must be completed.)

FULL NAME COMPLETE MAILING ADDRESS American Society for Microbiology 1913 I Street, N.W. L. Washington, D.C. 20006

8. KNOWN BONDHOLDERS, MORTGAGEES, AND OTHER SECURITY HOLDERS OWNING OR HOLDING 1 PERCENT OR MORE OF TOTAL AMOUNTA U% OFts^C BONDS.U MORTGAGES ORf% . OTIHER1r. SECURITIEl..~ -S((IftIhere are none, so state) FULL NAME COMPLETE MAILING ADDRESS None

9. FOR COMPLETION BY NONPROFIT ORGANIZATIONS AUTHORIZEDTO) MAIL AT SPECIAL RATES (SectIon 423.12 DfM only) The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes (Check one) 111 12) r HAS NOT CHANGED DURING '- HAS CHANGED DURING (If changed, publishier must subtnit explanation of Ug PRECEDING 12 MONTHS J PRECEDING 12 MONTHS chiange with this statement.) 10. AVERAGE NO. COPIES EACH ACTUAL NO. COPIES OF EXTENTEXTENTANDANDNATURENATUROF CIRCULATIONISSUECIRCULATION DURING PRECEDING ISSUE PUBLISHED NEARESTSINGLETO (See instructions onceverse side) 12 MONTHS FILING DATE A. TOTAL NO. COPIES (NetPress RunJ 8,500 8,500 B. PAID AND/OR REQUESTED CIRCULATION 1. Sales through dealers and carriers, street vendors and counter sales _ _ __ 2. Mail Subscription (Paid andlor requested) 6,608 7,205 C. TOTAL PAID AND/OR REQUESTED CIRCULATION 6 608 7 205 (Sum of JOB] and 10nB2J 6 7 D. FREE DISTRIBUTION BY MAIL, CARRIER OR OTHER MEANS SAMPLES. COMPLIMENTARY, AND OTHER FREE COPIES 61 61 E. TOTAL DISTRIBUTION (Sum of Cand D) 6,669 7,266 F. COPIES NOT DISTRIBUTED 1. Office use, left over, unaccounted spoiled after printing 1 ,831 1,234

2. Return from News Agents __-_

G. TOTAL (Sum of E. Fl and 2-should equal net press run shown leA) 8,500 8,500

11 I,*. \N._ ITSIGNATUREow~~~~~~~~~UFMPurs IJP%PAND TITLEIF OFrcEDITOR PUBLISHERUDLIZIMCM' tSUWFCbbBUSINFSS MANAUtitMMANAGFR nRtH UWVNtlHtWNFR Icertify that thestatements made by J A,' 6i v I Acting Director, Publicat ion me above are correct and complete CLd'M " r4r __ __ F_rm J B (e s s r e PS Form 3526, July 1984 (See instruction on reverse) AUTHOR INDEX VOLUME 28

Acar, J. F., 458 Buccini, Frank, 601 da Silva, H. R., 36 Furman, P. A., 181 Acevedo, Hernan F., 589 Buck, R. E., 761 Davis, Robin, 74 Acevedo, Hernan O., 589 Buckley, Joyce A., 138 Davis, S. S., 211 Galeazzi, Luciano, 419 Ackerman, Valentine P., 96 Burge, Lurinda J., 698 De Clercq, Erik, 84, 246 Gallalee, James V., 723 Actis, Luis A., 176 Burnham, W. R., 211 de Groot, Kees, 643 Gambertoglio, John, 535 Adloff, Michel, 311 Burns, William H., 740 de la Torre, Manuel Gardia, Ganzinger, U., 473 Ahmedy, Ali, 351 Butzler, Jean-Paul, 378 222 Garcia, Juan F., 128 Alaghamandan, Hassan, 375 Buu-Hoi, A., 458 Delgado, Timothy F., 589 Garden, G. M. F., 425 Aldridge, Kenneth, 675 Bygdeman, Solgun, 393 Delmas, Claude L., 351 Garty, Moshe, 489 Aldridge, Kenneth E., 634 Byrd, Richard G., 33 de Neeff, Janine, 824 Gary-Bobo, Claude M., 167 Alvarez, Salvador, 689 Dent, J., 837 Gerding, D. N., 849 Amend, William, 535 Cafferkey, Mary T., 819 de Pauw, Ben, 824 Ghazzouli, Ismail, 740 Andrews, Richard J., 815 Calia, Frank M., 735 Desrochers, Carmen, 711 Gianfrilli, Paola, 847 Anwar, Hosmin, 195 Call, Evan W., 375 de Witte, Theo, 824 Gibson, Robert N., 778 Arai, Tadashi, 5 Cameron, Fiona H., 96 Dick, James D., 597 Ginsburg, Charles M., 504 Ariza, J., 548 Carbon, Claude, 607 Domagala, John M., 766 Giovenella, A. J., 660 Ashby, J., 425 Cardines, Rita, 847 Dominguez-Gil, A., 544 Giunta, Sergio, 419 Asmar, Basim I., 138 Carlier, Cecile, 421 Donta, Sam T., 500 Glupczynski, Y., 756 Asselman, Chantal, 378 Caron, Michel, 123 Doraiswamy, Brinda, 508 Goldstein, Ellie J. C., 160 Carr, Daniel J. J., 578 Dougherty, Thomas J., 90, Goldstein, Fred, 452 Baars, Anita M., 654 Carr, Michael E., 413 200 Gonzalez, M. A., 235 Bailey, Denis M., 786 Casin, Isabelle M., 315 Dowling, John N., 730 Gooch, W. Manford, lll, 343 Bakker-Woudenberg, Irma A. Cerruti, Richard L., 1 Drusano, George L., 442 Gootz, Thomas D., 69 J. M., 654 Chalkley, L. J., 331 Drusano, G. L., 235 Gorbach, Sherwood L., 675 Baldwin, William W., 626 Chan, Lap-Yu, 274 Drutz, David J., 437 Gordon, Katherine P., 69 Baquero, Fernando, 113 Chapman, Michael, 165 Dubost, Maurice, 630 Gordts, Bart, 378 Barbeau, Gilles, 713 Chau, P. Y., 461 duBouchet, Lorraine, 508 Gotz, Vincent P., 727 Barriere, Steven L., 55 Chen, Ming S., 740 Dulworth, Jacqueline K., 745 Grappel, Sarah F., 660 Barry, D. W., 181 Cheng, Nick, 842 Durack, David T., 751 Gratz, Jean C., 428 Bartlett, Karen H., 842 Cheng, Yuan Rong, 678 Duran, S., 235 Gregoire, Sylvie, 123 Barton, Nancy, 265 Chernow, Marlene, 240 Duval, Jean, 421 Griffin, Hugh B., 413 Barug, Daniel, 643 Cherubin, Charles, 601 Griffin, Timothy J., 766 Bayer, Arnold S., 51, 781 Chisholm, D. R., 761 Ederer, Mary N., 381 Groner, Michael C., 64 Benjamin, Irving S., 778 Chong, Yunsop, 282 Elharrif, Zoubida, 695 Groppa, Giuseppe, 419 Bergeron, Michel G., 123, Chow, Anthony W., 842 Eliopoulos, George M., 78, Grossato, Anna, 678 320, 349, 404, 713 Chu, Kin-Wah, 639 514 Gudiol, F., 548 Berk, Steven L., 689 Chumpitaz, Jorge C., 452 Ellis, M. N., 181 Guerrero, Antonio, 222 Berkowitz, Frank E., 207 Chung, Hee-Young, 282 Eng, Robert H. K., 601 Berman, Jonathan D., 723 Citron, Diane M., 160 Engle, Jeannette C., 146 Haag, Ranier, 456 Bien, Paul A., 766 Clark, Nancye C., 154 Eron, Lawrence J., 308 Haanen, Clemens, 824 Bihl, Julie, 133 Cleary, Timothy, 675 Evans, Hugh E., 149 Haataja, H., 812 Biron, K. K., 181 Cohen, Michael A., 766 Evans, Martin E., 41 Habib, Nagy, 778 Bittner, Marvin J., 299 Colacino, Joseph M., 252 Hall, Leo M., 265 Blaser, Jurg, 64 Coleman, David C., 413 Fader, Robert C., 118 Haller, I., 663 Blenkharn, J. Ian, 778 Collatz, Ekkehard, 315 Falkiner, Frederick R., 413 Hammerschlag, Margaret R., Blickle, Jean-Fr6ddric, 311 Colley, Nigel, 165 Fan, Sheung-Tat, 639 508 Bloomfield, Sally F., 289 Cone, Lawrence A., 33 Fang, L. S. T., 46 Hara, Kohei, 15 Blumer, Jeffrey L., 839 Congeni, Blaise L., 508 Fass, Robert J., 834 Hardisson, C., 163 Blumgart, Leslie H., 778 Connell, Edward V., 1 Federspiel, Charles F., 41 Hare, Roberta S., 282 Bodet, C. Adrien, III, 437 Conrad, Dennis A., 58 Feingold, David S., 532 Harvey, Lisa, 308 Boehme, Richard, 240 Contrepois, Alain, 607 Fennell, Cynthia L., 188 Haslberger, A., 473 Bolard, Jacques, 167 Cook, P. Dan, 375 Fernandez-Viladrich, P., 548 Hayden, Frederick G., 216 Bornemann, L. D., 46 Cooksey, Robert C., 154 Finegold, Sydney M., 675 Heifets, Leonid B., 570 Bosso, John A., 829 Cotter, Julie L., 118 Fitzgerald, Faith T., 347 Heifetz, Carl L., 766 Bothof, Theo, 824 Courvalin, Patrice, 421 Fleishaker, J. C., 369 Hellfn, Teresa, 222 Bouvet, Anne, 607 Cowan, Ronald I., 839 Flores, Becky M., 188 Helsel, Valerie L., 834 Bouza, Emilio, 222 Cox, Phyllis A., 508 Flynn, Neil M., 347 Hemelhof, Wim, 378 Brajtburg, Janina, 144 Creger, Richard J., 839 Fontana, Roberta, 678 Henry, D., 259 Brammer, Keith W., 815 Cremieux, Anne C., 607 Forrest, A., 235 Herbst, John J., 829 Bran, Jose Luis, 128 Crokaert, F., 756 Forsgren, Arne B., 12 Herndon, David N., 118 Brander, Elias E., 157 Cronberg, Stig N., 12 Foster, Timothy J., 413 Hill, Gail, 675 Branger, C., 458 Crosa, Jorge H., 176 Foucault, Paule, 349 Hirschman, Shalom Z., 706 Brideau, Roger J., 485 Cuchural, George J., Jr., 675 Fradkin, Rochelle, 612 Hitzig, W. H., 667 Brocks, V. M., 46 Cunningham, Eloise J., 21 Fransen, Lieve, 393 Hixon, Deborah L., 308 Brogard, Jean-Marie, 311 Cushion, Melanie T., 796 Freeman, Donna J., 103 Hoffman, Howard E., 216 Brown, Allen L., 791 Cynamon, Michael H., 440 Freitas, Vicki R., 240 Hoger, P. H., 667 Brown, Michael R. W., 195 Frola, Frank N., 730 Holdrinet, Rob, 824 Brunham, Robert C., 393 Dajani, Adnan S., 138 Fujita, Kiyo, 15 Holmes, King K., 141, 188 Brunson, Kenneth W., 626 Daly, Judy A., 343 Fukuda, Yoshiaki, 15 Holzhoffer, Sonja, 456 Bryan, Joe P., 361 Danziger, Larry H., 839 Fulton, Robert W., 698 Hone, Rosemary, 819 i ii AUTHORINDEX ANTIMICROB. AGENTS CHEMOTHER.

Hoogmartens, Jos, 630 Kondo, Hisao, 684 McLaren, Colin, 740 Pasculle, A. William, 730 Hooper, David C., 581, 716 Koornhof, H. J., 331 McNamara, P. J., 369 Patel, I. H., 46 Hopfer, Roy L., 511 Koskela, Markku, 354 McNulty, C. A. M., 425 Patterson, Lyndell S., 41 Horowitz, Edward A., 299 Koup, Jeffrey R., 74 McNulty, Cliodna A. M., 837 Paulin, Lars G., 157 Houang, Elizabeth T., 165 Koutsky, Laura A., 141 McPherson, Gilbert A. D., Pdrez-Diaz, J. Claudio, 113 Howard, Jorge, 282 Kratz, Luisa, 612 778 Perfect, John R., 751 Hsieh, Wei-Chuan, 282 Kubo, Hiroaki, 514 Medoff, Gerald, 144 Peters, Jeanne, 552 Huffman, John H., 375 Kumada, Teppei, 282 Megraud, Francis, 695 Peterson, L. R., 849 Humphrey, M. J., 648 Kumar, Kusum, 149 Mehta, Kapil, 511 Petitjean, Pierre, 630 Huovinen, Pentti, 354 Mehta, Reeta T., 511 Petruska, Mary, 504 Huovinen, Saara, 354 Lally, Richard T., 381 Mejia, Carlos R., 128 Phillips, L., 660 Hurwitz, Aryeh, 489 Lam, Selina, 540 Mendoza, M. C., 163 Pichardo, A., 235 Hylands, Peter J., 289 Lamesch, Catherine, 607 Merlet-Benichou, Claudie, 565 Pierson, Carl, 675 Langford, Marlyn P., 578 Meulemans, Alain, 565 Piot, Peter, 393 lannini, Paul, 675 Larsson, Sture, 12 Meunier-Carpentier, F., 467 Pitkin, D. H., 660 Ikewaki, Nobunao, 28 Latorre, Cristina, 357 Meyer, Joachim F., 302 Plorde, James J., 69 Inamine, Edward, 478 Lau, Wan-Yee, 639 Meyer, Richard, 478 Plummer, Francis, 393 Ing6lfsd6ttir, Kristin, 289 Lavoie, Gadtan Y., 320, 404 Meyers, Burt R., 706 Polis, Michael A., 576 Inoue, Kunio, 684 Lawrence, Francoise, 528 Michel, Marc F., 654 Ponte, Carmen, 845 Inoue, Matsuhisa, 684, 773 LeBel, Marc, 123, 713 Mikami, Yuzuru, 5 Poretz, Donald M., 308 Inoue, Michiko, 192 LeBlanc, Donald J, 141 Miller, George H., 282 Poso, Hannu J., 157 Iseman, Michael D., 570 Leclercq, Roland, 421 Milne, Robert W., 293 Preheim, Laurel C., 299 Ito, Hideharu, 192 Lee, How-Sung, 540 Minami, Shinzaburou, 773 Price, K. E., 761 Izumikawa, Kinichi, 15 LeFrock, Jack L., 133 Minocha, Anil, 216 Proctor, Richard A., 691 Legrand, J. C., 467 Misiek, M., 761 Pugsley, Mary P., 299 Jackson, Julius H., 21 Lehrman, S. N., 181 Mitsuhashi, Susumu, 684, 773 Pulkkinen, Leena, 354 Jacobs, Richard F., 791 Leitner, F., 761 Moellering, Anne E., 514 Pursiano, T. A., 761 Jacobus, Nilda V., 675 Lelievre-Pegorier, Martine, Moellering, Robert C., Jr., 78, Jacoby, George A., 703 565 514 Raikow, Radmila B., 589 Janda, J. Michael, 151 Lembke, Lois A., 500 Moestrup, Torkil, 12 Ramirez, Claudio A., 128 Janney, Ailleen, 634 Lessard, Celine, 349 Mok, Daniel, 778 Rapp, Fred, 449 Jehl, Franqois, 311 Lett, Marie-Claire, 351 Monteil, Henri, 311 Reig, Milagro, 113 Jevons, S., 648 Leung, Y. K., 461 Monteiro, Edmund H., 540 Reiszner, Edina, 514 John, Lindsay, 778 Levi, Michael A., 730 Moody, J. A., 849 Rice, Vicki, 552 Johnson, David E., 735 Levin, Myron J., 207 Moranchel, A. H., 235 Richardson, Kenneth, 815 Johnson, Jonas T., 832 Levol, Georgette, 630 Mordenti, Joyce, 55 Ritchie, Lyndal J., 96 Jokipii, Anssi M. M., 561 Levy, Patrick, 311 Morikawa, Masako, 192 Robert-Gdro, Malka, 528 Jokipii, Liisa, 561 Lifland, Patti W., 146 Morningstar, Jean, 172 Roberts, Marilyn C., 141, 176 Jones, Fred, 21 Lilley, Cynthia, 118 Morris, J. Glenn, Jr., 442 Robins, Roland K., 375 Jones, Mary, 689 Lindholm-Levy, Pamela J., Motyl, Mary R., 151 Rocha, Heonir, 361 Jones, Steven, 832 570 Mudaliar, Yugan, 293 Rodriguez-Barbero, J., 544 Jones, Terry E., 293 Linke, Michael J., 796 Rodriguez-Crdixems, Marta, Jordan, M. Colin, 172 Lior, Hermy, 708 Nagasawa, Masao, 15 222 Jorgensen, James H., 437 Lismont, M. J., 756 Nahmias, Andrd J., 552 Roets, Eugene, 630 Juliano, Rudolph L., 511 Llaneza, J., 163 Nakayama, Chikao, 326 Romero-Vivas, Josd, 222 Juncosa, Teresa, 357 Lopez, Carlos, 252 Nakazato, Hiroko, 15 Rosenfeld, Warren, 149 Lopez-Berestein, Gabriel, 511 Nearman, Howard S., 839 Rosenwirth, Brigitte, 246 Kadurugamuwa, Jagath L., Luzzi, Ida, 847 Newman, David J., 494 Rossan, Richard N., 612 195 Ng, Lai-King, 708 Rossi, Lucia, 678 Kakizawa, Hiromi, 773 Maeda, Akio, 5 Ng, W. S., 461 Roy, Rejean, 349 Kanes, Wanda, 570 Magana, J. L., 235 Ngui-Yen, J., 259 Rubin, R. H., 46 Kania, Stephen A., 107 Mannisto, P. T., 812 Nies, Berthold A., 302 Rufi, G., 548 Karachalios, George N., 693 Marchand, Anne-Marie, 695 Nisbet, L. J., 660 Keane, Conor T., 819 Marifio, E. L., 544 Nisbet, Louis J., 494 Sabatelli, Frank J., 282 Kearns, Gregory L., 791 Marks, Melvin I., 58 Nishikawa, Takashi, 514 Safranek, Thomas J., 299 Keller, P. M., 181 Marriott, Michael S., 815 Nishiyama, Yukihiro, 326 Saikawa, Isamu, 773 Kenny, George E., 141 Martin, J. L., 181 Norman, Dean, 781 Saito, Atsushi, 15 Kenny, Michael T., 745 Martinez-Beltran, JesCs, 222 Nsanze, Herbert, 393 Saito, Kazuhisa, 28 Khan, Abdul J., 149 Martinez-Suarez, Joaquin V., Saito, Saburo, 28 Kibwage, Isaac Ongubo, 630 113 0ie, Svein, 535 Sakly, Rachid, 565 Kim, Ha-Kyung Cho, 832 Maserati, Renato, 428 Obbink, Derk J. Groot, 96 Salas, J. A., 163 Kim, Kwang Sik, 51, 389, Matsen, John M., 829 O'Brien, J., 211 Sampaoli, Giuseppe, 419 433, 781 Matsuda, Kouji, 684 Oka, Kitaro, 192 Sande, Merle A., 361 Kiminki, Olli, 354 Matsushita, Kazuko, 227 O'Keefe, J. Paul, 675 Sanders, Charles V., 634 Kingsbury, William D., 494 Matthews, Thomas R., 240 Olson, Kurt, 504 Sanders, Christine C., 299 Klastersky, J., 467 Mattick, John S., 96 Ozasa, Diane C., 55 Saneyoshi, Mineo, 326 Kliebe, Christine, 302 Mattila, Timo, 354 Sanfeliu, Isabel, 357 Kluza, Ronald B., 791 McCann, William P., 265 Painter, B., 235 Sansom, Lloyd N., 293 Kobayashi, George S., 144 McCarthy, Peter J., 494 Pallards, R., 548 Sanson-Le Pors, Marie-Jose, Kobayashi, Yoshie, 514 McCracken, George H., Jr., Pantosti, Annalisa, 847 315 Kobos, Denise M., 138 504 Paolantonacci, Philippe, 528 Santamaria, Margarita, 845 Koga, Hironobu, 15 McDevitt, David A., 730 Pardo, Matias, 589 Saral, Rein, 740 Koldin, Malcolm H., 144 McKinley, Geoffrey, 151 Pascal, Claude, 630 Sasaki, Kazumi, 684 VOL. 28, 1985 AUTHOR INDEX iii

Satta, Giuseppe, 678 Srulevitch, Elina S., 706 Tolxdorff-Neutzling, Regina Weber, Allan, 74 Saukkonen, Jussi J., 200 Stamm, Walter E., 188 M., 302 Weber, Andrew H., 58 Sawai, Tetsuo, 227 Stanforth, David, 796 Tomonaga, Akimitsu, 15 Weisser, Jochen, 700 Sawatari, Katsuhiko, 15 Stenberg, Kjell, 802 Torney, Harry L., 745 Wells, Thomas G., 791 Schaberg, Dennis R., 446 Stoltzman, David S., 33 Townsend, Paula L., 829 Wennersten, Christine, 78 Schaeffer, Henry A., 149 Stone, Benjamin B., 64 Trang, John M., 791 White, Robert A., 511 Scheld, W. Michael, 361, 428 Stratton, Charles W., 41 Tribukait, Bernhard, 802 Whitley, Richard J., 265 Schinazi, Raymond F., 552 Strunk, Roger W., 428 Troke, Peter F., 815 Wiedemann, Bernd, 302, 700 Schleupner, Charles J., 146 Suarez, J. E., 163 Trown, Patrick W., 1 Wilhelmi, Isabel, 845 Schmidt, L. H., 612 Sud, Inder J., 532 Tsai, Y. H., 761 Williams, Keith, 824 Schulemann, Werner, 612 Suen, Hon-Chi, 639 Tsuboi, Minoru, 192 Williamson, Joanne M., 478 Scorneaux, B., 37 Sullivan, Roger, 612 Tsutsumi, Masayoshi, 28 Williams-Warren, Judy, 74 Scott, R. Taylor, 552 Sunila, Ritva, 354 Tuazon, Carmelita U., 576 Wilson, P., 211 Scribner, Ronald K., 58 Sussmuth, Roland, 456 Turchetti, Gianni, 419 Wise, R., 425, 837 Sedlock, David M., 786 Sutton, Lorraine, 703 Turgeon, Pierre L., 711 Wolcott, Judith A., 485 Seger, R., 667 Suzuki, Satoru, 326 Wolfson, John S., 581, 716 Selman, Warren R., 839 Suzuyama, Yoji, 15 Underwood, Fred L., 791 Wong, Kwok-Kee, 639 Shanley, John D., 172 Swenson, Jana M., 807 Utsui, Yukio, 397 Wong, P. C. L., 461 Shermantine, Maria, 535 Woodard, David R., 33 Sheth, Nitin V., 103 Tadakuma, Takushi, 28 Vallee, Francois, 713 Woolfrey, Bert F., 381 Sheu, Michael J.-T., 626 Takahashi, Katsuhiro, 5 Vallois, Jean-Marie, 607 Wrzos, Helena, 449 Shigeno, Yoshiteru, 15 Takai, Akira, 773 van den Berg, Joke C., 654 Shimizu, Kihachiro, 282 Tally, Francis P., 675 Van der Auwera, P., 37, 467 Yamaguchi, Keizo, 15 Shockley, Thomas E., 21 Tanaka, Michiyasu, 227 Vanderhaeghe, Hubert, 630 Yamamoto, Tomoko, 227 Shull, Virginia H., 597 Tansino, Gary F., 508 Van der Linden, M. P., 756 Yasuda, Takashi, 773 Siber, George R., 107 Tarbit, M. H., 648 Varghese, Mathew, 149 Yasuda, Tatsuji, 28 Sidwell, Robert W., 375 Tausk, Francisca, 41 Verbist, Ludo, 630 Yazawa, Katsukiyo, 5 Silcox, Vella A., 807 Taveres, Aida, 361 Vdrtut-Croquin, Aline, 167 Yim, Connie Whiteside, 347 Siler, William, 265 Taylor, Diane E., 452, 708 Vidon, Dominique J.-M., 351 Yin-Murphy, Marguerite, 578 Skidmore, A. G., 259 Tenney, James H., 442 Viitanen, J., 812 Yiu, Tim-Fuk, 639 Yokota, Takeshi, 397 Skog, Sven, 802 Tenover, Fred C., 69 Villar, C. J., 163 Yoshida, Shonen, 326 Slaney, Leslie, 393 Textor, Jacquelyn A., 691 Vincenti, Flavio, 535 Yost, Richard L., 727 Smee, Donald F., 240 Thabet, Michel, 349 Vosbeck, K., 667 Yotsuji, Akira, 773 Smith, A., 259 Thauvin, Claudie, 78 Vree Tom B., 654 Young, Stephen A., 69 Smith, Arnold L., 74 Thirumoorthi, M. C., 138 Yourassowsky, E., 756 Smith, Bruce R., 133 Thompson, Bruce, 735 Wagner, Robin L., 832 Yu, Victor L., 832 Smith, J. A., 259 Thornsberry, Clyde, 154, 807 Walder, Mats H., 12 Smith, Sharon M., 601 Thys, J. P., 467 Wallace, Richard J., Jr., 807 Zak, Oto, 195 Soriano, Francisco, 845 Ti, Teow-Yee, 540 Wallace, Sylvia M., 274 Zeiler, H.-J., 52 Spruance, Spotswood L., 103 Toivanen, Paavo, 354 Walzer, Peter D., 796 Zervos, Marcus J., 446 Spyker, Daniel A., 216 Tolkoff-Rubin, N. E., 46 Warren, H. Shaw, 107 Zinner, Stephen H., 64 SUBJECT INDEX VOLUME 28

A-56619 candidiasis, 511 Arabinosylhypoxanthine activity in vitro, 514 C. neoformans, 751 high-pressure liquid chromatography, A-56620' combinations 265 activity in vitro, 514 muramyl dipeptide analog, 511 Aridicins Absorption experimental infections activities, 660 oral , 727 C. albicans endocarditis, 751 Arildone Acycloyir cryptococcal meningitis, 751 acute hemorrhagic conjuntivitis viruses, cytomegalovirus, 172, 240 lipoprotein-complexed 578 experimental infections serum cholesterol elevation, 144 combinations herpes simplex virus, X toxicity, 144 interferon, 578 herpes simplex virus, 103 liposome-encapsulated resistance patterns, 740 candidiasis, 511 combinations lung infection, 172 transfer from gel state vesicles, 167 ciprofloxacin, 849 pneumonitis, 172 Ampicillin Adjuvants absorption bacterial infections, 222 rectal absorption, 211 lactobacillus effects, 727 H. influenzae, 404 Aerobic bacteria comnbinations penetration SK&F 88070, 343 penetration into pelvic peritoneum, fibrin clots, 404 Aeromonas caviae 165 interstitial fluid, 404 susceptibility, 151 , 165 Aeromonas hycrophila Corynebacterium group D2, 845 Bacteremia susceptibility, 151 E. coli BMY-28142, 51 Aeromonas sobria suprainhibitory concentrations, 756 , 33 susceptibility, 151 H. influenzae, 404 E. coli, 51 Amnantadine hydrochloride mice group B streptococci, 51 , 216 morphine effects , 33 Amdinocillin penetration tobramycin, 33 pharmacokinetics, 46 fibrin clots, 404 Bacterial infections renal insufficiency, 46 interstitial fluid, 404 aztreonam, 222 Amikacin pharmacokinetics Bacteroides fragilis comnbinations morphine effects, 489 ceftazidime, 781 resistance P-lactamase inactivation, 773 endocarditis, 607, 781 N. gonorrhoeae, 21 cephamycin inactivation, 733 enterococci, 78 Ampicillin-chloramphenicol 2-methyl-5- compounds , 78, 607 experimental infections carnidazole, 562 , 607 dimetridazole, 562 comparative activity E. coli bacteremia, 433 , 562 ceftazidime', 735 meningitis, 433 ornidazole, 562 piperac'illin, 735 Ampicillin-gentamicin panidazole, 562 endocarditis, 607, 781 experimental infections secnidazole, 562 experimental infections E. coli bacteremia, 433 , 562 endocarditis, 607 meningitis, 433 susceptibility P. aeruginosa, 735 Ansamycin nationwide study, 675 P. aeruginosa comparative activity Bacteroides uniformis endocarditis, 781 MDL 473, 440 chloramphenicol resistance, 113 P. aeruginosa experimental infections, rifampin, 440 R plasmid, 113 735 Mycobacterium avium complex Biliary excretion Amiloride MICs, 570 , 778 antistreptococcal activity, 419 Mycobacterium intracellulare, 440 BMY-28142 Aminoglycoside Antileishmanial drugs bacteremia, 51 interaction with ,-lactam , activity in vitro cystic fibrosis isolates, 58 274 Aminoglycosides semiautomated assessment, 723 E. coli, 51 2"-O-adenylyltransferase, 69 Antineoplastic agents group B streptococci, 51 ,NA hybridization; 69 antibacterial activities, 437 meningitis, 51 phosphotransferases Antiprotozoal drugs pediatric pathogens, 58 H. ducreyi, 311 Giardia lamblia, 378 plasmid-mediated, 311 Antistreptococcal activity Campylobacter coli resistance patterns, 282 amiloride, 419 macrolides, 695 triamterene, 419 Campylobacter jejuni combinations Appendicitis clavulanic acids, 37 , 165 P-lactams P-lactams, 37 penetration into pelvic peritoneum, treatment, 639 macrolides, 695 165 1-3-D-Arabinofuranosyl-5-fluorouracil sulbactam, 37 Amoxicillin-clavulanic acid cytomegalovirus'inhibition, 326 Campylobacter-like organisms comparative activity Arabinosyladenine susceptibility, 188 co-trimoxazole, 693 high-pressure liquid chromatography, Campylobacter pyloridis urinary tract infections, 693 265 susceptibility, 837 urinary tract infections, 693 Arabinosyladenine-5 '-monophosphate Campylobacter spp. high-pressure liquid chromatography, susceptibility C. albicans, 751 265 DNA gyrase inhibitors, 708 iv VOL. 28, 1985 SUBJECT INDEX v

enoxacin, 708 Cefoxitin pharmacokinetics nalidixic acid, 708 adjuvants, 211 septicemic rabbits, 473 Candida albicans experimental infections resistance experimental infections K. pneumoniae pneumonia in rats, plasmid-coded, 302 mice, 815 654 Cephalothin UK-49, 858, 815 K. pneumoniae, 654 Corynebacterium group D2, 845 lombazole, 643 rectal absorption, 211 Cephamycin peptidyl drug transport rates, 494 serum protein binding B. fragilis UK-49, 858 K. pneumoniae pneumonia in rats, ,B-lactamase inactivation, 773 mice, 815 654 CGP 11637 ultrastructure experimental ihfections lombazole, 643 comparative activity, 133 oncogenic viruses, 589 Candidiasis ih vitro evaluation, 133 oncogenic viruses, 589 amphotericin B Chloramphenicol liposome-encapsulated, 511 comparative activity B. uniformis resistance, 113 prophylaxis, 511 , 160 resistance Carnidazole ceftazidime, 160 H. ducreyi, 176 Bacteroides spp., 562 enterococci, 160 H. parainfluenzae, 176 comparative activity P. aeruginosa, 160 5-(2-Chloroethyl)-2'-deoxyuridine 2-methyl-5-nitroimidazole compounds, S. aureus, 160 herpes simplex virus, 246 562 S. epidermidis, 160 CI-934 Ceftazidime in vitro activity, 766 comparative activity, 834 bacteremia, 33 Cilastatin pharmacokinetics, 425 clinical comparisons, 299 superoxide dismutase activity, 691 tissue penetration, 425 combinations Ciprofloxacin amikacin, 781 aminoglycoside combinations, 663 comparative activity endocarditis, 781 biliary elimination, 311 ceftazidime, 146 , 824 clinical efficacy, 128 pneumonia, 146 in vitro pharmacokinetics, 64 combinations netilmicin, 64 aminoglycosides, 663 experimental infections P. aeruginosa, 64 azlocillin, 849 K. pneumoniae pneumonia in rats, comparative activity Enterobacteriaceae, 663 654 amikacin, 735 P. aeruginosa, 663 K. pneumnoniae, 654 cefamandole, 146 comparative activity serum protein binding cefotaxime, 160 azlocillin plus tobramycin, 428 K. pneumoniae pneumonia in rats, cefpirome, 160 P. aeruginosa endocarditis, 428 654 piperacillin, 735 E. coli, 331 endocarditis high-pressure liquid chromatography, children P. aeruginosa, 781 311 clinical efficacy, 508 enterococci, 160 log-phase E. coli, 524 safety, 508 experimental infections resistance experimental infections P. aeruginosa, 735 S. aureus, 634 E. coli bacteremia, 389 neutropenic patients microbiological assay, 311 meningitis, 389 empiric treatment, 824 oral formulations, 74 flucloxacillin combination, 824 P. aeruginosa, 308, 331, 428 pharmacokinetics P. aeruginosa, 160 pharmacokinetics, 74, 235 intramuscular administration, 544 endocarditis, 781 S. aureus, 331 intravenous administration, 544 P. aeruginosa experimental infections, synergy, 331 735 Clavulanic acid infants pharmacokinetics C. jejuni, 37 pharmacokinetics, 149 elderly humans, 713 combinations serum bactericidal activity, 55 pneumonia, 33, 146 amoxicillin, 165 Cefotaxime S. aureus, 160 comparative activity, 259 cerebrospinal fluid diffusion, 138 S. epidermidis, 160 penetration itto pelvic peritoneum, comparatie activity urinary tract infections, 299 165 cefpirome, 160 ticarcillin, 259 ceftazidime, 160 serum bactericidal activity, 55 Clostridium difficile P-lactams, 842 desacetylcefotaxime, 791 blister fluid penetration, 123 quinolones, 842 enterococci, 160 comparative activity , 847 experihlental infections ampicillin plus chloramphenicol, 361 vancomycin, 847 E. coli bacteremia, 433 meningitis, acute bacterial, 361 nonapeptide meningitis, 433 typhoid fever, 540 lipopolysaccharides meningitis, 138 binding, 107 pharmacokinetics, 791 H. influenzae, 404 neutralization, 107 P. aeruginosa, 160 penetration Continuous ambulatory peritoneal dialysis pharmacokinetics fibrin clots, 404 moxalactam kinetics, 293 meningitis, 791 interstitial fluid, 404 Corynebacterium group D2 S. aureus, 160 Cefuroxime axetil ampicillin, 845 S. epidermidis, 160 bactericidal activity, 504 cephalothin, 845 serum bactericidal activity, 55 pharmacokinetics, 504 erythromycin, 845 gentamicin, 845 lower respiratory tract infections, 576 K. pneumoniae surface antigens, 195 norfloxacin, 845 ,vi SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

novobiocin, 845 5-Ethyl-2'-deoxyuridine rifampin, 845 syphilis, 347 experimental infections tetracycline, 845 herpes simplex virus, 552 vancomycin, 845 Endocarditis herpes simplex virus, 103, 552 Co-trimoxazole ciprofloxacin Experimental infections comparative activity P. aeruginosa, 428 C. albicans endocarditis, 751 amoxicillin-clavulanic acid, 693 combinations cryptococcal meningitis, 751 urinary tract infections, 693 amikacin-ceftazidime, 781 E. coli bacteremia urinary tract infections, 693 P. aeruginosa ampicillin-chloramphenicol, 433 Coumermycin amikacin, 781 amnpicillin-gentamicin, 433 comparative activity ceftazidime, 781 cefmenoxime, 389 S. aureus, 706 ciprofloxacin, 428 cefotaxime, 433 methicillin resistance Enoxacin -cilastatin, 433 S. aureus, 634 Campylobacter spp., 708 endocarditis S. aureus comparative activity, 259 amikacin, 781 methicillin-resistant, 706 Campylobacter spp., 708 ceftazidime, 781 Cystic fibrosis DNA gyrase inhibitors, 708 herpes simplex virus BMY-28142, 58 nalidixic acid, 708 acyclovir, 1 netilmicin pharmacokinetics, 829 Enterobacteriaceae 5-ethyl-2'-deoxyuridine, 552 Cytomegalovirus ciprofloxacin-aminoglycoside combina- interferon, 1 acyclovir, 240 tions, 663 Legionella micdadei, 730 1-p-D-arabinofuranosyl-5-fluorouracil, ,-lactams meningitis 326 inoculum effect, 601 ampicillin-chloramphenicol, 433 2'-deoxy-2'-fluoro-,-D-arabinofurano- Enterococci ampicillin-gentamicin, 433 syl-5-iodocytosine, 252 amikacin, 78 cefmenoxime, 389 9-(1,3-dihydroxy-2-propoxymethyl) gua- cefotaxime, 160 cefotaxime, 433 nine, 240 cefpirome, 160 imipenem-cilastatin, 433 human skin fibroblasts, 252 ceftazidime, 160 oncogenic viruses murine penicillin, 78 CGP 11637, 589 acyclovir, 172 trimethoprim-sulfamethoxazole suscepti- P. aeruginosa 9-(1,3-dihydroxy-2-propoxymethyl) bility amikacin, 781 guanine, 172 susceptibility reversal by folinic acid, ceftazidime, 781 interstitial pneumonitis, 172 446 endocarditis, 781 lung infection, 172 Enzyme-linked immunosorbent assays phosphanilic acid, 761 pyrimidone treatment, 485 infected cell monolayers, 207 picornavirus selective inhibition, 326 varicella-zoster virus, 207 phenoxypyridinecarbonitriles, 745 Enzymuria 2'-Deoxy-2'-fluoro-,-D-arabinofurano- gentamicin, 500 Feline calcivirus syl-5-iodocytosine tobramycin, 500 interferon, 698 cytomegalovirus, 252 Erythromycin Feline herpesvirus 1 human skin fibroblasts, 252 Corynebacterium group D2, 845 interferon, 698 Desacetylcefotaxime Erythromycins Fibroblasts cefotaxime, 791 A through D human skin meningitis MICs, 630 cytomegalovirus, 252 pharmacokinetics, 791 2'-deoxy-2'-fluoro-,3-D-arabinofur- pharmacokinetics ampicillin anosyl-5-iodocytosine, 252 meningitis, 791 suprainhibitory concentrations, 756 Flucloxacillin Dibekacin bacteremia, 51 combinations HPLC BMY-28142, 51 ceftazidime, 824 determination in serum, 521 cefmenoxime, 389 neutropenic patients Diffusional clearance model, 369 ciprofloxacin, 331 ceftazidime combination, 824 9-(1,3-Dihydroxy-2-propoxymethyl) gua- DNA gyrase inhibitors, 200 Fluoroquinolones nine experimental infections activity spectra, 581 comparative activity, 240 ampicillin-chloramphenicol, 433 clinical uses, 716 cytortegalovirus, 172, 240 ampicillin-gentamicin, 433 mechanisms of action, 581 lung infection, 172 bacteremia, 389, 433 mechanisms of resistance, 581 pneumonitis, 172 cefmenoxime, 389 pharmacology, 716 cefotaxime, 433 structures, 581 bimetridazole imipenem-cilastatin, 433 toxicities, 716 Bacteroides spp., 562 P-lactamases, 703 Folinic acid comparative activity P-lactam resistance, 703 enterococci 2-methyl-5-nitroimidazole compounds, log phase reversal of trimethoprim-sulfamethox- 562 ciprofloxacin, 524 azole susceptibility, 446 DNA gyrase inhibitors membrane permeability, 200 Foscarnet Campylobacter spp. meningitis, 51 cell cycle comparative activity piperacillin concentration-dependent effects, 802 Campylobacter spp., 708 suprainhibitory concentrations, 756 enoxacin, 708 stationary phase combinations nalidixic acid, 708 ciprofloxacin, 524 S. aureus, 689 E. coli, 200 Ethambutol enymatic modification, 163 DNA hybridization dextro isomer, 157 plasmid-mediated resistance, 163 aminoglycoside Mycobacteria spp. spermidine synthe- S. aureus 2"-O-adenylyltransferase, 69 sis, 157 methicillin-resistant, 689 VOL. 28, 1985 SUBJECT INDEX vii

Gene probes Human brucellosis S. faecium gentamicin resistance, 96 rifampin-doxycycline, 548 hypersusceptibility, 678 TEM f3-lactamases, 154 tetracycline-streptomycin, 548 Legionella micdadei Gentamicin experimental infections, 730 N-acetyl-3-D-glucosaminidase excretion Imipenem Legionella pneumophila tobramycin comparison, 500 comparative activity, 259 experimental infections combinations P. aeruginosa resistance, 41 pneumonia, 15 endocarditis, 607 stability ofloxacin, 15 penicillin, 607 Mueller-Hinton agar at 4°C, 711 Leishmania spp. vancomycin, 607 Imipenem-cilastatin multiplication Corynebacterium group D2, 845 experimental infections sinefungin, 528 endocarditis, 607 E. coli bacteremia, 433 Leuconostoc sp. experimental infections meningitis, 433 vancomycin resistance, 458 endocarditis, 607 Influenza viruses A and B Lichen metabolites fetal tissues selenazofurin, 375 antimicrobial activity, 289 guinea pigs, 565 Interferon Lincomycin kinetics combinations S. haemolyticus guinea pigs, 565 arildone, 578 plasmid-mediated resistance, 421 resistance experimental infections Lipopolysaccharides gene probe, 96 herpes simplex virus, 1 binding, 107 Germicidal agents feline colistin nonapeptide, 107 octenidine hydrochloride, 786 feline calcivirus, 698 neutralization, 107 Giardia lamb/ia feline herpesvirus 1, 698 Lipoproteins antiprotozoal drugs, 378 nonoxynol 9 amphotericin B synergy against herpes simplex virus serum cholesterol elevation, 144 Haemophiluis ducreyi type 2, 449 toxicity, 144 aminoglycoside phosphotransferase, 311 recombinant human leukocyte Listeria monocytogenes chloramphenicol-resistant, 176 feline calcivirus, 698 susceptibility, 12 molecular characterization, 176 feline herpesvirus 1, 698 Lombazole Haemnophiluis influtenzae C. albicans ampicillin, 404 Kanamycin ultrastructure, 643 aztreonam, 404 HPLC S. epidermidis cefuroxime, 404 determination in serum, 521 ultrastructure, 643 13-lactams, 320 Ketoconazole Lung infections SK&F 88070, 343 combinations acyclovir, 172 tolerance, 320 sterol synthesis inhibitors, 532 cytomegalovirus, 172 Haemophilus paraiinflluenzae fungal growth, 532 9-(1,3-dihydroxy-2-propoxymethyl) gua- chloramphenicol-resistant, 176 Klebsiella pneulnoniae nine, 172 molecular characterization, 176 cefazolin, 654 5-(2-Haloalkyl)pyrimidine cefoxitin, 654 Macrolides nucleoside analogs cephalosporins, 195 C. coli, 695 herpes simplex virus, 246 experimental infections C. jejluni, 695 Herpes simplex virus cefazolin, 654 Malaria acyclovir, 103 cefoxitin, 654 RC-12, 612 resistance patterns, 740 rats, 654 MCP-1 5-(2-chloroethyl)-2'-deoxyuridine, 246 protein antigens, 195 cytotoxicity for tumor cells, 626 5-ethyl-2'-deoxyuridine, 103 MCP-2 experimental infections 1-Lactamase cytotoxicity for tumor cells, 626 acyclovir, 1 B. firagilis MDL 473 5-ethyl-2'-deoxyuridine, 552 cephamycin inactivation, 773 comparative activity interferon, 1 E. coli, 703 ansamycin, 440 5-(2-haloalkyl)pyrimidine nucleoside an- gene probe, 154 rifampin, 440 alogs, 246 OXA-1 Mwcobacterium intraceelulare, 440 nonoxynol 9, 449 transposon, 227 Meningitis interferon, 449 TEM type, 154 BMY-28142, 51 plaque autoradiography assay, 181 ,B-Lactams cefotaxime, 138 thymidine kinase mutants, 181 appendicitis ceftriaxone, 361 High-pressure liquid chromatography treatment, 639 E. coli, 51 arabinosyladenine, 265 C. difficile, 842 experimental infections arabinosyladenine-5'-monophosphate, ampicillin-chloramphenicol, 433 C. jejiuni, 37 ampicillin-gentamicin, 433 265 diffusional clearance model, 369 cefmenoxime, 389 arabinosylhypoxanthine, 265 Enterobacteriaceae cefotaxime, 433 ciprofloxacin, 311 inoculum effect, 601 imipenem-cilastatin, 433 comparative studies, 311 H. itflitenzae, 320 group B streptococci, 51 dibekacin N. gonoirrhoeae resistance, 90 Metronidazole determination in serum, 521 P. (ieruginosa resistance, 41 Bacteroides spp., 562 kanamycin penicillin-binding proteins, 678 comparative activity determination in serum, 521 penicillins 2-methyl-5-nitroimidazole compounds, pipemidic acid, 192 interaction with aminoglycosides, 274 562 ticarcillin, 597 pharmacokinetics, 369 genital tissue concentrations, 812 HR 810 resistance Microbiological assays see cefpirome E. coli, 703 ciprofloxacin, 311 viii SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

comparative studies, 311 Novobiocin Pharmacokinetics Morphine Corynebacterium group D2, 845 amantadine hydrochloride, 216 ampicillin disposition, 489 amdinocillin, 46 Moxalactam Obstructive jaundice ampicillin cerebrospinal fluid penetration piperacillin, 778 morphine effects, 489 ventriculostomy patients, 839 Octenidine hydrochloride f3-lactams, 369 clinical comparisons, 299 germicidal agent, 786 carumonam, 425 continuous ambulatory peritoneal dialy- Ofloxacin cefmetazole, 544 sis, 293 L. pneuinophila, 15 cefoperazone, 149 kinetics, 293 pneumonia, 15 ceftazidime serum bactericidal activity, 55 Oncogenic virus infections elderly humans, 713 urinary tract infections, 299 prevention cephalosporins Muramyl dipeptide analog CGP 11637, 589 rabbits, 473 candidiasis, 511 Ophthalmia neonatorum ciprofloxacin, 74, 235 combinations N. gonorrhoeae isolates netilmicin amphotericin B, 511 susceptibility, 393 cystic fibrosis patients, 829 Mycobacteria Ornidazole rimantadine hydrochloride, 216 rapidly growing, 807 Baccteroides spp., 562 sulfisoxazole ethambutol, 157 comparative activity renal transplant patients, 535 spermidine synthesis, 157 2-methyl-5-nitroimidazole compounds, , 832 Mycobacterium avium complex 562 UK-49,858, 648 ansamycin N-D-Ornithyl amphotericin B Phenoxypyridinecarbonitriles MICs, 570 C. albicans, 751 antipicornavirus activity, 745 Mycobacteriuin chelonace C. neoformnans, 751 Phosphanilic acid subgroups, 807 experimental infections combinations Mycobacterium fortuitumn C. albicans endocarditis, 751 trimethoprim, 761 subgroups, 807 cryptococcal meningitis, 751 Picornaviruses Mycobacteriumn intraccellulare experimental infections, 745 ansamycin, 440 combinations phenoxypyridinecarbonitriles, 745 MDL 473, 440 rifampin, 467 Pipemidic acid rifampin, 440 placebo-controlled study, 467 high-pressure liquid chromatography, Mycoplasma hominis rifampin 192 streptococcal tetM sequences, 141 staphylococcal infections, 467 Piperacillin tetracycline resistance, 141 staphylococcal infections Biliary excretion, 778 Mycoplasmna spp. rifampin, 467 comparative activity, 259 amphotericin B transfer, 167 Staphylococcus aiureus amikacin, 735 permeability, 167 tolerance, 381 ceftazidime, 735 potassium transport, 167 E. coli Panidazole suprainhibitory concentrations, 756 Nalidixic acid Baccteroides spp., 562 experimental infections Ca'npylobacter spp., 708 comparative activity P. aieruginosa, 735 comparative activity 2-methyl-5-nitroimidazole compounds, obstructive jaundice, 778 Campylobacter spp., 708 562 P. aeruginosa experimental infections, DNA gyrase inhibitors, 708 Pediatric infections 735 enoxacin, 708 cefmenoxime Plaque autoradiography clinical efficacy, 508 herpes simplex virus, 181 ampicillin resistance, 21 safety, 508 Plasmids 13-lactam resistance, 90 Pediatric pathogens elimination Ophthalmia neonatorum isolates, 393 BMY-28142, 58 4-quinolones, 700 penicillin-binding proteins, 90 Penicillin gram-negative bacteria, 413 structure, 90 combinations multiply resistant Ro 15-8074, 461 amikacin, 78, 607 molecular analysis, 413 susceptibility endocarditis, 607 resistance ophthalmia neonatorum isolates, 393 enterococci, 78 cephalosporins, 302 Neplanocins gentamicin, 607 Sallmonella typhi, 452 antimetabolic activities, 84 comparative activity S. haemolyticus, 421 antiviral activities, 84 vancomycin, 607 Sallmonella typhi Netilmicin endocarditis, 607 IncHIl variability, 452 combinations experimental infections trimethoprim resistance, 452 ceftazidime, 64 endocarditis, 607 Pneitinocystis ccarinii in vitro pharmacokinetics, 64 Penicillin-binding protein susceptibility test, 796 P. aeruiginosa, 64 S. aiureus Pneumonia dosage requirements -resistant, 397 cefamandole, 146 cystic fibrosis patients, 829 methicillin-resistant, 397 ceftazidime, 33, 146 pharmacokinetics Penicillin-binding proteins L. pneuimophila, 15 cystic fibrosis patients, 829 3-lactam hypersusceptibility, 678 ofloxacin, 15 Nonoxynol 9 N. gonosrrhloeae, 90 ticarcillin, 33 interferon S. faeciumn, 678 tobramycin, 33 synergy against herpes simplex virus Pneumonitis type 2, 449 N. gonorrlioeae, 90 acyclovir, 172 Norfloxacin Peptidyl drugs cytomegalovirus, 172 Corynebacterium group D2, 845 transport rates 9-(1,3-dihydroxy-2-propoxymethyl) gua- tissue penetration, 349 C. albicans, 494 nine, 172 VOL. 28, 1985 SUBJECT INDEX ix

Polymorphonuclear leukocytes IncHl1 plasmid, 452 Streptococcus pneuinoniae rifampin, 667 Salmonellosis resistance, 357 Protein binding S. enteritidis, 28 serotypes, 357 cefazolin, 654 streptomycin, 28 Streptomyces cattleya cefoxitin, 654 Sch 34343 reverse transsulfuration activity, 684 biosynthesis, 478 cefotaxime, 160 stability Streptomyces lavendulae cefpirome, 160 ,-lactamases, 684 saframycin biosynthesis, 5 ceftazidime, 64, 160 renal dehydropeptidase 1, 684 Streptomycin ciprofloxacin, 308, 331, 428 Secnidazole salmonellosis, 28 ciprofloxacin-aminoglycoside combina- Bacteroides spp., 562 S. enteritidis, 28 tions, 663 comparative activity Sulbactam endocarditis 2-methyl-5-nitroimidazole compounds, C. jejuni, 37 ciprofloxacin, 428 562 combinations netilmicin, 64 Selenazofurin ampicillin, 165 resistance influenza A and B viruses, 375 penetration into pelvic peritoneum, imipenem, 41 Sinefungin 165 1-lactams, 41 Leishmania spp. Sulfisoxazole Pyrimidone effect on multiplication, 528 pharmacokinetics cytomegalovirus infection, 485 SK&F 88070 renal transplant patients, 535 aerobic cocci, 343 Sultamicillin Quinolones H. influenzae, 343 pharmacokinetics, 832 A-56619, 514 Sodium hypochlorite sinusitis A-56620, 514 antimicrobial activity, 118 pharmacokinetics, 832 C. difficile, 842 chemical parameters, 118 therapeutic trial, 832 4-Quinolones tissue toxicity, 118 therapeutic trial, 832 plasmid elimination, 700 Spermidine Superoxide dismutase synthesis, 157 cilastatin, 691 Rabbit macrophage peptides Susceptibility testing MCP-1 cefotaxime, 160 N. gonorrhoeae, 393 cytotoxicity for tumor cells, 626 cefpirome, 160 Syphilis MCP-2 ceftazidime, 160 doxycycline, 347 cytotoxicity for tumor cells, 626 cephem-resistant RC-12 penicillin-binding protein, 397 Teicoplanin antimalarial activity, 612 ciprofloxacin, 331 C. difficile, 847 subacute toxicity, 612 coumermycin, 706 cholestyramine interactions, 847 Renal insufficiency fosfomycin, 689 comparative activity amdinocillin pharmacokinetics, 46 methicillin-resistant vancomycin, 847 Resistance ciprofloxacin, 634 methicillin resistance B. fragilis coumermycin, 634, 706 S. aureus, 634 nationwide study, 675 penicillin-binding protein, 397 Tetracycline Respiratory tract infections septicemia, 819 Corynebacterium group D2, 845 cefotiam, 576 teicoplanin, 634 M. hominis resistance, 141 Rifampin oscillating tolerance in synchronized Tetracycline-streptomycin combinations cultures, 456 human brucellosis, 548 oxacillin, 467 oxacillin tolerance, 381 Thienamycin comparative activity Staphylococcus epidermidis S. cattleya ansamycin, 440 cefotaxime, 160 reverse transsulfuration, 478 MDL 473, 440 cefpirome, 160 Ticarcillin Corynebacterium group D2, 845 ceftazidime, 160 combinations Mycobacterium intracellulare, 440 lombazole, 643 bacteremia, 33 oxacillin ultrastructure clavulanic acid, 259 staphylococcal infections, 467 lombazole, 643 comparative activity, 259 placebo-controlled study, 467 Staphylococcus haemolyticus pneumonia, 33 polymorphonuclear leukocytes, 667 lincomycin ticarcillin, 33 staphylococcal infections, 467 plasmid-mediated resistance, 421 HPLC determination, 597 oxacillin, 467 Streptococci Tinidazole Rifampin-doxycycline group B Bacteroides spp., 562 human brucellosis, 548 comparative activity Rimantadine hydrochloride bacteremia, 51 2-methyl-5-nitroimidazole compounds, pharmacokinetics, 216 BMY-28142, 51 562 Ro 15-8074 meningitis, 51 genital tissue concentrations, 812 N. gonorrhoeae, 461 tetM sequences Tissue fluid kinetics M. hominis, 141 diffusional clearance model, 369 Saframycin vancomycin resistance, 458 Tissue penetration derivatives Streptococ cus faecium carumonam, 425 biosynthesis, 5 hypersusceptibility, 678 Tobramycin S. lavendulae, 5 P-lactams N-acetyl-p-D-glucosaminidase excretion Salmonella enteritidis hypersusceptibility, 678 gentamicin comparison, 500 salmonellosis, 28 low-affinity penicillin-binding proteins, combinations streptomycin, 28 678 bacteremia, 33 Salmonella typhi resistance pneumonia, 33 trimethoprim resistance transition to hypersusceptibility, 678 ticarcillin, 33 x SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.

Triamterene U-63196E penicillin, 607 antistreptococcal activity, 419 see cefpimizole teicoplanin, 847 Triazoles UK-49,858 Corynebacterium group D2, 845 UK-49,858 C. albicans endocarditis pharmacokinetics, 648 mice, 815 experimental infections Trimethoprim experimental infections endocarditis, 607 combinations C. albicans, 815 Varicella-zoster virus phosphanilic acid, 761 mice, 815 enzyme-linked immunosorbent assay, resistance in fecal flora, 354 pharmacokinetics resistance plasmids animals, 648 207 Salmonella typhi, 452 humans, 648 infected cell monolayers, 207 Trimethoprim-sulfamethoxazole Urinary tract infections Vibrio spp. enterococci ceftazidime, 299 norfloxacin, 442 susceptibility reversal by folinic acid, moxalactam, 299 446 folinic acid Vancomycin Yersinia enterocolitica susceptibility reversal, 446 C. difficile, 847 susceptibility, 351 Tumor cells cholestyramine interactions, 847 Yersinia frederiksenii mice combinations susceptibility, 351 MCP-1, 626 amikacin, 607 Yersinia intermedia MCP-2, 626 endocarditis, 607 susceptibility, 351 Typhoid fever gentamicin, 607 Yersinia kristensenii ceftriaxone therapy, 540 comparative activity susceptibility, 351